FBLG — FIBROBIOLOGICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
FBLG FAQ
What is FBLG's ROE?
FIBROBIOLOGICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -718.46%.
What is FBLG's dividend yield?
FIBROBIOLOGICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is FBLG's Deepscope Quality Score?
Deepscope rates FBLG's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FBLG?
Deepscope's AI Timing Score for FBLG is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FBLG belong to?
FIBROBIOLOGICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.93
Price
-0.03
(-3.42%)
Day Change
|
|
|---|
FBLG, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 69 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.93 |
| PBV / Sector |
1.93 / 4.91
|
| Earning Per Share | -3.46 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
0.13 M
GREAT
|
| Average 1W Daily Value |
0.11 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:50 |
| Symbol | FBLG |
| Name | FIBROBIOLOGICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.21 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5.02 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 455 East Medical Center Boulevard, Houston, TX, United States, 77598
Phone: 281 671 5150
Website: https://fibrobiologics.com
Sector: Healthcare >> Biotechnology
Description: FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google